omega-3 fatty acid

(redirected from Omacor)
Also found in: Dictionary, Thesaurus.
Related to Omacor: Lovaza

omega-3 fatty acid

n.
Any of several polyunsaturated fatty acids that are essential for human metabolism, have anticoagulant properties, and are found in leafy green vegetables, vegetable oils, nuts, and fish such as salmon and mackerel. Increasing dietary intake of omega-3 fatty acids can decrease serum concentrations of triglycerides and LDL cholesterol while increasing HDL cholesterol.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

omega-3 fatty acid

, ?-3 fatty acid
Any of the long-chain polyunsaturated fatty acids found in the oils of some saltwater fish, and in canola, flaxseed, walnuts, and some vegetables. These acids include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Alpha-linolenic acid (found in flaxseed and chia) can be metabolically converted to omega-3 fatty acids in the body. People whose diets are rich in omega-3 fatty acids have a reduced incidence of cardiovascular disease. Synonym: n-3 fatty acid
See also: acid
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Omacor is also approved in key European and certain Asian markets for the secondary prevention of post-myocardial infarction, or Post-MI, the period following the initial survival of a heart attack.
That makes it much more potent than most of the over-the-counter fish oil supplements, and because it is produced according to FDA's good manufacturing practice standards, Omacor may be of higher quality than OTC supplements, said William Harris, Ph.D., director of lipid research at the Mid America Heart Institute in Kansas City, Mo.
Omacor has been tested on 11,000 heart-attack survivors and the results showed that it reduced all deaths by 20% and sudden deaths by 45.
11 May 2011 - Norwegian company Pronova BioPharma ASA (OSL: PRON) said Tuesday that a pivotal phase 3 clinical trial of the omega-3 product Omacor (TAK-085), carried out by Japanese partner Takeda Pharmaceutical Co (TYO: 4502), showed better results than an approved product.
The dose of fish oil used is approximately equivalent to 1.5 g of the recently approved Omacor fish oil capsules.
As a result of its Operational Excellence Programme, GSK will reduce inventory levels of Pronova's product Omacor, which is branded Lovaza in the USA.
Six months since the patent for its Omacor product, based on omega-3 fatty acids, in Europe expired, and so far, no generic products have come on the market.
In July the solution alerted pharmacies of a Food and Drug Administration-mandated change of the drug name Omacor to Lovaza.
Omacor was approved as an adjunct to diet to help reduce triglycerides in patients with levels above 500 mg/dL.
Last year Pronova Biocare introduced Omacor in Europe, also as a prescription drug, with 90% EPA Ethyl Ester as the active, and more recently Reliant Pharmaceutical introduced Omacor into the U.S.